| Ytd | 109.93% | |
| 1y | 393.33% |
| Open | 18.43 | Prev Close | 18.71 | Low | 17.67 | High | 19.00 | Mkt Cap | 3.87B |
| Vol | 3.36M | Avg Vol | 4.36M | EPS | -1.56 | P/E | N/A | Forward P/E | -11.33 |
| Beta | 1.75 | Short Ratio | 7.91 | Inst. Own | 86.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 14.59 | 200-d Avg | 9.88 | 1yr Est | 24.82 |
RLAY News
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weight
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises t
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYS
Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company
Raymond James analyst Dane Leone maintains Relay Therapeutics (NASDAQ:RLAY) with a Strong Buy and
Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowes
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the ana
Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and r
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig
Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling effi
Jones Trading analyst Boris Peaker initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a
Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig
Relay Therapeutics shares rise after Phase 3 data show zovegalisib achieved 11.1-month PFS in metast
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises t
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig
Oppenheimer analyst Matthew Biegler upgrades Relay Therapeutics (NASDAQ:RLAY) from Perform to Out
Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in
Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weigh
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all pati
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.